Abstract
This article describes recent medicinal chemistry progress toward selective potentiators of the metabotropic glutamate receptor 2 (mGluR2). Groups at Lilly and Merck have identified new classes of potentiators that exhibit selectivity for mGluR2 over the seven other subtypes of mGluRs. Structure-activity relationships as well as pharmacokinetic properties and in vivo activity are reviewed.
Keywords: glutamate, mglur, group II, potentiator, agonist
Current Topics in Medicinal Chemistry
Title: Positive Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 2 (mGluR2)
Volume: 5 Issue: 9
Author(s): Michael T. Rudd and John A. McCauley
Affiliation:
Keywords: glutamate, mglur, group II, potentiator, agonist
Abstract: This article describes recent medicinal chemistry progress toward selective potentiators of the metabotropic glutamate receptor 2 (mGluR2). Groups at Lilly and Merck have identified new classes of potentiators that exhibit selectivity for mGluR2 over the seven other subtypes of mGluRs. Structure-activity relationships as well as pharmacokinetic properties and in vivo activity are reviewed.
Export Options
About this article
Cite this article as:
Rudd T. Michael and McCauley A. John, Positive Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 2 (mGluR2), Current Topics in Medicinal Chemistry 2005; 5 (9) . https://dx.doi.org/10.2174/1568026054750281
DOI https://dx.doi.org/10.2174/1568026054750281 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidative Stress in the Molecular Mechanism of Pathogenesis at Different Diseased States of Organism in Clinics and Experiment
Current Drug Targets - Inflammation & Allergy Analysis of Functional Brain Images Using Population-Based Probabilistic Atlas
Current Medical Imaging Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer
Current Medicinal Chemistry TRPV1 Channel: A Potential Drug Target for Treating Epilepsy
Current Neuropharmacology Current Developments of Coumarin Compounds in Medicinal Chemistry
Current Pharmaceutical Design GABAA Receptor Channel Pharmacology
Current Pharmaceutical Design Epidemiology of Major Congenital Malformations with Specific Focus on Teratogens
Current Drug Safety Phentermine and Topiramate Extended-Release for the Obesity: New Kids on the Block
Recent Patents on Cardiovascular Drug Discovery Obstructive Sleep Apnea Syndrome: From Phenotype to Genetic Basis
Current Genomics Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging
Current Medicinal Chemistry N-acetylcysteine Versus Placebo for Treating Nail Biting, a Double Blind Randomized Placebo Controlled Clinical Trial
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Development, Recent Achievements and Current Directions of Research into GABA Uptake Inhibitors
Current Medicinal Chemistry Random Walks on Biomedical Networks
Current Proteomics Editorial [Hot topic: The Urokinase Receptor System as Strategic Therapeutic Target: Challenges for the 21st Century (Executive Guest Editor: Bernard Degryse)]
Current Pharmaceutical Design The Molecular Genetics of Migraine: Toward the Identification of Responsible Genes
Current Genomics Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Emerging Pharmacological Properties of Cholinergic Synaptic Transmission: Comparison between Mammalian and Insect Synaptic and Extrasynaptic Nicotinic Receptors
Current Neuropharmacology Spatio-Temporal Fluctuations of Neural Dynamics in Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Current Gene Therapy Diabetes, Cognitive Function, and the Blood-Brain Barrier
Current Pharmaceutical Design